Laryngectomy Clinical Trials

Clinical trials related to Laryngectomy Procedure

A Single-Arm, Open-Label Study of Intralesional Treatment of Laryngeal Squamous Cell Carcinoma With Cisplatin

Status: Recruiting
Location: See location...
Intervention Type: Procedure, Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

The purpose of this study is to determine the effects, good and bad, of injecting chemotherapy into recurrent laryngeal squamous cell carcinoma (SCC) tumors.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Men and women 18 years and older.

• Previously treated for laryngeal SCC with radiation.

• Must have biopsy-proven recurrent cancer requiring surgical management. Note: if participants do not have an archived tissue sample available for review, they may undergo a biopsy procedure for collection of a fresh tissue sample for diagnostic confirmation and determination of further treatment. In this case, a fresh tumor sample would be used for diagnostic confirmation and trial eligibility. Please note, this biopsy would be considered a standard of care (SOC) procedure since it is being performed for disease management purposes regardless of participant enrollment in the trial.

• Participants must be willing to undergo 3 weekly cycles of IC under local anesthesia prior to surgery.

• Adequate hematologic, hepatic, and renal function tested within 6 weeks prior to the start of therapy (values must not be achieved with growth factors):

‣ Absolute neutrophil count (ANC) ≥ 1.0 × 10\^9 cells /L.

⁃ Hemoglobin ≥ 8.0 g/dL.

⁃ Platelet count ≥ 50 × 10\^9 platelets/L.

⁃ Total bilirubin ≤ 1.5 × upper limit of normal (ULN).

⁃ Alanine transaminase (ALT)/aspartate aminotransferase (AST) ≤ 3.0 ULN.

⁃ Calculated creatinine clearance ≥ 45 mL/min by the Cockcroft-Gault Equation or the estimated glomerular filtration rate ≥ 45 mL/min/1.73 m2 using the Modification of Diet in Renal Disease formula.

• Willingness to avoid pregnancy based on the criteria below:

‣ Woman of non-childbearing potential (ie, surgically sterile with a hysterectomy and/or bilateral oophorectomy OR ≥ 12 months of amenorrhea and at least 45 years of age).

⁃ Woman of childbearing potential who has a negative urine or serum pregnancy test at screening and who agrees to take appropriate precautions to avoid pregnancy (with at least 99% certainty) from screening and for at least 14 months after the last dose of trial intervention. Permitted methods that are at least 99% effective in preventing pregnancy should be communicated to the participant and their understanding confirmed.

Locations
United States
Florida
University of Miami
RECRUITING
Miami
Contact Information
Primary
David E Rosow, MD
DRosow@med.miami.edu
+1 (305) 2432587
Time Frame
Start Date: 2026-12-01
Estimated Completion Date: 2031-09-01
Participants
Target number of participants: 20
Treatments
Experimental: Cisplatin + Epinephrine Group
Participants in this group will receive one (1) dose of intralesional chemotherapy (IC) treatment per week over a period of approximately 3 weeks. IC treatment will consist of combination cisplatin and epinephrine. Participants will then go to have endoscopic surgery for their disease.~Total participation duration is approximately 16 months.
Related Therapeutic Areas
Sponsors
Leads: University of Miami

This content was sourced from clinicaltrials.gov